Navigation Links
Niutang Sucralose Patent Litigation Successfully Concluded
Date:6/1/2009

Tate & Lyle will not appeal ITC decision; Voluntarily dismisses District Court case

BREA, Calif., June 1 /PRNewswire/ -- Changzhou Niutang, one of the largest global manufacturers of sucralose, and its U.S. subsidiary, US Niutang, today announced that Tate & Lyle will not appeal the recent decision made by the U.S. International Trade Commission that decisively rejected Tate & Lyle's infringement allegations against Niutang. In addition, Tate & Lyle has requested a voluntary dismissal of the patent infringement allegations it brought against Niutang in the United States District Court.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090528/CG23830LOGO)

"We are delighted to have all aspects of this litigation successfully concluded, with a complete victory in favor of Niutang," said Licheng Wang Jr., General Manager of Changzhou Niutang. "We will continue to focus our attention on what we do best - providing the highest quality sweeteners and food additives along with outstanding service to our worldwide customers."

Niutang has steadily grown its sucralose customer base, which now spans North America, Central America, South America, Europe and Asia. Niutang is already one of the largest manufacturers of aspartame in the world, and it has built upon that successful track record in growing its sucralose business.

"Niutang's sucralose sales have more than tripled from 2007 to 2008," continued Wang. "We recently completed the expansion of our sucralose capacity to 300 metric tons and have announced our plans to increase our capacity to 500 metric tons by 2012. As our sucralose business continues to grow, we remain committed to providing our customers with the high-quality products and unsurpassed level of customer service they have come to expect from Niutang."

Niutang is one of the largest and most experienced global manufacturers of sucralose. The company's established track record is built upon the highest standards of quality control, with products that are:

  • Manufactured according to cGMP requirements as stated in CFR 21 Part 110
  • Produced to meet all quality specifications required by current FCC
  • Moody International ISO 9001:2000/cGMP/HACCP certified
  • Kosher and Halal certified
  • Registered with the U.S. FDA in accordance with the Security and Bioterrorism Preparedness and Response Act of 2002

About Niutang

Niutang Chemical is one of the world's leading manufacturers and distributors of food additives, chemicals and pharmaceutical intermediates that are instrumental to food, beverage, pharmaceutical, nutraceutical and industrial products. Established in 1969, Niutang's commitment to producing the highest quality food additives at competitive prices has ensured its rapid growth into a leading global manufacturer of aspartame, folic acid, and more recently, sucralose. The company is certified in meeting the most stringent U.S. and European manufacturing, compliance and quality benchmarks. Based in China, Niutang also has sales and quality control operations in the United States and Europe that support its strong reputation for integrity and customer service. The company's website is www.niutang.com. For inquiries regarding Niutang Sucralose sales, please contact sales@niutang.us.

    For more information:

    Doreen Lubeck
    DJ Lubeck, LLC
    773-583-4331
    djlubeck@yahoo.com


'/>"/>
SOURCE Niutang Chemical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Niutang to Expand Sucralose Capacity 66 Percent by 2012
2. Niutang Recruits Seasoned Executive to Open U.K. Office
3. GDFII/L&P Sucralose Win Over Competitor Tate & Lyle
4. SENOMYX RECEIVES GENERALLY RECOGNIZED AS SAFE (GRAS) DETERMINATION FOR S2383 SUCRALOSE ENHANCER
5. Falcon Genomics Awarded Patent for Innovative Cancer Test
6. Viral Genetics Has Option Under Issued Key Patent for Cancer Drug
7. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
8. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
9. Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force
10. Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
11. Palomar Wins Two European Hair Removal Patent Opposition Hearings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... “The Road To Restoration”: an informative and enlightening ... hour a week showing of hands. “The Road To Restoration” is the creation of ... familiar with the brass ring that you could reach out for, and grab, on ...
(Date:12/7/2016)... ... 07, 2016 , ... “Fred Rides a Train” allows readers to tag along ... “Fred Rides a Train” is the creation of published author, Janet Morrison, who has ... in Michigan. The "Fred, the Dog" series is her first attempt at writing for ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to reduce ... drinking more water or limiting their exposure to the sun, according to a November ... group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ourselves ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems (NYSE: ... its previously announced plans to separate its Imaging Components ... a tax-free distribution to Varian stockholders of common stock ... that will hold the Imaging Components business.  As part ... executed by the end of January 2017, Varian will ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
Breaking Medicine Technology: